The Indian pharmaceutical industry is the world’s 3 largest in the world by volume & 14th largest by value
India growing as the medical tourism hub of the world by providing cost effective treatment with the latest high tech solution.
India has been strong in the pharma sector, with an affordable cost of manufacturing. 30% -35% more affordable than the US & Europe without compromising the quality of medicine and medical devices. Cost-efficient R&D is about 87% less than the developed market of the world because of skilled labour available at low cost. Indian youth is the power engine of the growth of the country. Due to Affordable prices and high quality Indian medicine is mostly preferred worldwide and India become the pharmacy of the world.
India is the only country with the largest number of US-FDA compliant plants (more than 262 including APIs) outside of the USA. We have nearly 1400 WHO-GMP-approved Pharma Plants, and 253 European Directorate of Quality Medicines (EDQM) approved plants with modern state-of-the-art Technology. No other country can boast of such an infrastructure.
India has a share of 60% of vaccine production in the world. India plays a significant role in COVID-19 vaccine R&D, production, and supply to the world. India fulfills the WHO demand for 70% of Diphtheria, Tetanus, and Pertussis (DPT) and Bacillus Calmette–Guerin (BCG) vaccines and 90% of the WHO demand for the measles vaccine. Affordable HIV treatment is the greatest achievement of India.
The pharmaceutical industry in India is currently valued at US$50 billion and is expected to reach US$57 billion by 2025.
The total market size of India’s pharma industry is expected to reach US$130 billion by 2030 and US $450 billion by 2047.
India’s export of drugs and pharmaceuticals US$27.85 billion in FY 2023-24
/
